Welcome to the NeuroGenomics and Informatics (NGI) group

The NeuroGenomics and Informatics Group is a multidisciplinary team working at the forefront of personalized medicine.

The goal of the NeuroGenomics and Informatics Group is to understand the biology of neurodegeneration by using high-dimensional omic data and functional genomic approaches.

We leverage these approaches to identify novel genetic variants, genes and pathways implicated in disease, to identify new molecular biomarkers and novel therapeutic targets.

News

MS4A4A is the mayor regulator of TREM2 levels

MS4A4A is the mayor regulator of TREM2 levels

Drs. Harari, Benitez, Karch and Cruchaga leveraged biospecimens obtained from large and well-characterized human cohorts to identify a novel protective gene for Alzheimer disease, MS4A4A, that is also the major regulator of TREM2. This study provides a strong evidence of a biological link between TREM2 and MS4A4A in microglia in the context of AD. However, […]

Drs. Cruchaga and Karch receive new funding to advance personalized medicine in Alzheimer Disease

Drs. Cruchaga and Karch are some of the Washington University investigators that received funding from Centene to perform molecular phenotyping of Alzheimer's cases to identify novel molecular biomarkers and the identification of novel therapeutically targets. Specifically we plan to develop a personalized medicine approach to understand the effects of Alzheimer’s disease risk genes by combining […]

Tweets by NGI